Browse studies

Find your next paid study

27,370 recruiting studies available now

A Randomized, Multicenter, Multiregional, Pivotal Clinical Trial to Evaluate the Safety and Efficacy of IMD10 (Focused Ultrasound) in Combination With the Chemotherapy Regimen Consisting of Irinotecan Hydrochloride, Oxaliplatin, Fluorouracil (5-FU) and Leucovorin Improves Overall Survival Compared With the Chemotherapy Regimen Alone in Patients With Borderline Resectable Pancreatic Cancer or Locally Advanced Pancreatic Cancer

The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable …

Pancreatic CancerBorderline Resectable Pancreatic CancerLocally Advanced Pancreatic Cancer

Estimated

~$10 – $1,050

Actual pay is set by the research site.

IMGT Co., Ltd.NCT07325214

Observational

Implementation Supports to Reduce Burnout in Therapists Delivering Child Trauma EBPs

The majority of children exposed to early adversity and trauma do not have access to sustainably delivered evidence-based mental health programs (EBPs), despit…

Mental Health Issue

Estimated

~$10 – $750

Actual pay is set by the research site.

San Diego State UniversityNCT04712461

Phase 4

Pioglitazone, Lipotoxicity, and Heart Failure With Preserved Ejection Fraction (HFpEF)

Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main…

Type 2 Diabetes Mellitus in ObeseHeart Failure With Preserved Ejection Fraction

Estimated

~$25 – $1,000

Actual pay is set by the research site.

The University of Texas Health Science Center at San AntonioNCT05838287

Phase 1

Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)

This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in tre…

Locally Advanced Intrahepatic CholangiocarcinomaOligometastatic Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8+2 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Phase 1

Pilot Study of Scaling Busulfan Dose to Body Surface Area in Children Undergoing Hematopoietic Stem Cell Transplantation

The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-bande…

Busulfan Pharmacokinetic AnalysisBusulfan DosingHematopoietic Stem Cell Transplant (HSCT)+2 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Children's Hospital of PhiladelphiaNCT07792369

Phase 4

A Prospective, Randomized, Double-blind Trial of the Impact of Intraoperative Intravenous Lidocaine Infusion on Total Opioid Requirements in Children Undergoing Surgical Fixation of Upper Extremity Long Bone Fractures Under General Anesthesia

This study is a prospective, randomized, double-blind clinical trial evaluating whether intraoperative intravenous lidocaine infusion (IVLI) reduces opioid req…

Fracture ArmFracture Closed of Lower End of Forearm, UnspecifiedFracture Elbow+4 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Nemours Children's ClinicNCT07552766

Observational

Evaluating the Role of the Guidewire in Peripheral Intravenous Access: A Randomized Controlled Trial of Ultrasound-Guided Catheter Survival

This is a prospective, parallel, non-blinded, two-arm randomized controlled trial of intravenous catheter failure evaluating the impact of a built-in guide wir…

Peripheral Intravenous Vein Catheter PhlebitisIntravenous Infection

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Corewell Health EastNCT06107361

Observational

Single-Dose Stereotactic Radiosurgery (SDRT) as Definitive Non-Operative Treatment for Early-Stage Breast Cancer: A Prospective Single-Arm Pilot Trial With Bayesian Safety Monitoring (SOLIS / Protocol RAD 2024)

SOLIS is a prospective, single-arm, single-institution pilot trial evaluating single-fraction stereotactic radiotherapy (24 Gy to the planning target volume wi…

Breast CancerEarly-Stage Breast CarcinomaHormone Receptor-Positive Breast Cancer+1 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Renaissance Institute of Precision Oncology and RadiosurgeryNCT07844759

Observational

Visual Perception in Visual Snow Syndrome

The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to an…

Visual Snow SyndromeMigraineHealthy

Estimated

~$10 – $750

Actual pay is set by the research site.

University of MinnesotaNCT06961864

Observational

Development of a Culturally Adapted, Video-based Patient Education Intervention to Increase Diabetic Eye Screening and Teleophthalmology Use in Latinx Communities

An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how …

Diabetic Retinopathy

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Wisconsin, MadisonNCT06257082

Phase 2

A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Meningioma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Baptist Health South FloridaNCT05425004

Phase 1

An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in com…

Solid Tumor, Adult

Estimated

~$150 – $4,200

Actual pay is set by the research site.

CytomX TherapeuticsNCT06462794